CD22 and acute lymphoblastic leukemia: Anti-CD22 monoclonal antibodies including epratuzumab, moxetumomab pasudotox and the radioimmunoconjugate, 90Y-DOTA-epratuzumab, have been studied in R/R paediatric and adult ALL [80,81,82,83,84].